Adaptive Biotechnologies Corp ADPT Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Jan 13, 2021 (filed on Jan 15, 2021)

Insider Name:

Cohen Chad M

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right To Buy)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-50,000

Price:

--
Jan 13, 2021 (filed on Jan 15, 2021)

Insider Name:

Cohen Chad M

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-34,180

Price:

$63.63
Jan 13, 2021 (filed on Jan 15, 2021)

Insider Name:

Cohen Chad M

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-15,820

Price:

$62.92
Jan 13, 2021 (filed on Jan 15, 2021)

Insider Name:

Cohen Chad M

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

50,000

Price:

$6.32
Jan 12, 2021 (filed on Jan 13, 2021)

Insider Name:

Cohen Chad M

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right To Buy)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-75,000

Price:

--
Jan 12, 2021 (filed on Jan 13, 2021)

Insider Name:

Cohen Chad M

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-1,200

Price:

$63.73
Jan 12, 2021 (filed on Jan 13, 2021)

Insider Name:

Cohen Chad M

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-33,827

Price:

$62.96
Jan 12, 2021 (filed on Jan 13, 2021)

Insider Name:

Cohen Chad M

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-39,973

Price:

$62.25
Jan 12, 2021 (filed on Jan 13, 2021)

Insider Name:

Cohen Chad M

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

75,000

Price:

$6.32
Jan 12, 2021 (filed on Jan 13, 2021)

Insider Name:

Rubinstein Julie

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-15,000

Price:

--

Filings by filing date

Jan 13, 2021 (filed on Jan 15, 2021)

Insider Name:

Cohen Chad M

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right To Buy)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-50,000

Price:

--
Jan 13, 2021 (filed on Jan 15, 2021)

Insider Name:

Cohen Chad M

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-34,180

Price:

$63.63
Jan 13, 2021 (filed on Jan 15, 2021)

Insider Name:

Cohen Chad M

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-15,820

Price:

$62.92
Jan 13, 2021 (filed on Jan 15, 2021)

Insider Name:

Cohen Chad M

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

50,000

Price:

$6.32
Jan 12, 2021 (filed on Jan 13, 2021)

Insider Name:

Cohen Chad M

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right To Buy)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-75,000

Price:

--
Jan 12, 2021 (filed on Jan 13, 2021)

Insider Name:

Cohen Chad M

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-1,200

Price:

$63.73
Jan 12, 2021 (filed on Jan 13, 2021)

Insider Name:

Cohen Chad M

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-33,827

Price:

$62.96
Jan 12, 2021 (filed on Jan 13, 2021)

Insider Name:

Cohen Chad M

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-39,973

Price:

$62.25
Jan 12, 2021 (filed on Jan 13, 2021)

Insider Name:

Cohen Chad M

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

75,000

Price:

$6.32
Jan 12, 2021 (filed on Jan 13, 2021)

Insider Name:

Rubinstein Julie

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-15,000

Price:

--

News

Biz Brief

Sector: Healthcare	Industry: Biotechnology & Medical Research

See Regulatory Filings on SEC

Company Contact

Address:	1551 Eastlake Ave E Ste 200 SEATTLE WA 98102-7402
Tel:	N/A
Website:	https://www.adaptivebiotech.com
IR:	See website

Key People

Chad M. Robins Executive Chairman, Chief Executive Officer, Co-Founder	Charles Snag Senior Vice President - Clinical Diagnostics	Julie Rubinstein President
Harlan S. Robins Co-Founder, Chief Scientific Officer	Chad M. Cohen Chief Financial Officer	Francis Lo Chief People Officer
Stacy Taylor Senior Vice President, General Counsel	Sharon Benzeno Senior Vice President - Drug Recovery	Nancy Louise Hill Senior Vice President - Operations
Jyoti Palaniappan Senior Vice President - Clinical Diagnostics immunoSEQ Dx

Business Overview

Adaptive Biotechnologies Corp is a biotechnology company. The Company is focused on using the biology of the adaptive immune system to develop the diagnosis and treatment of disease. Its immune medicine platform generates clinical immunomics data to decode the adaptive immune system. Its products and pipeline includes immunoSEQ, clonoSEQ and cellular therapy. It offers its immunoSEQ technology as a service and a kit. immunoSEQ utilizes bias-controlled polymerase chain reaction (PCR) to sequence immune receptors from deoxyribonucleic (DNA). clonoSEQ is its diagnostic test product for the detection and next-generation sequencing (NGS)-based monitoring of minimal residual disease (MRD) in bone marrow samples in patients with myeloma (MM) and acute lymphoblastic leukemia (ALL). clonoSEQ is designed to sequence all rearranged receptor sequences in a tumor in parallel to enable MRD monitoring. It also focuses on developing immune-mediated therapies in oncology and other disease areas.

Financial Overview

For the nine months ended 30 September 2020,Adaptive Biotechnologies Corp revenues increased 12% to$68.2M. Net loss applicable to common stockholdersincreased from $49M to $101.7M. Revenues reflectDevelopment revenue segment increase of 45% to $39.5M.Higher net loss reflects Research and development -Balancing val increase of 59% to $74.3M (expense).

Employees:	453 as of Dec 31, 2019

Reporting Currency:	U.S. Dollars
Enterprise value:	$8,144M as of Sep 30, 2020
Annual revenue (TTM):	$92.41M as of Sep 30, 2020
EBITDA (TTM):	-$124.57M as of Sep 30, 2020
Net annual income (TTM):	-$122.27M as of Sep 30, 2020
Free cash flow (TTM):	-$148.48M as of Sep 30, 2020
Net Debt Last Fiscal Year:	N/A
Shares outstanding:	136,772,417 as of Oct 31, 2020
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

INK Ultra Money Free

INK Ultra Money Videos

Adaptive Biotechnologies Corp (OQ:ADPT)